The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
about
Surgical and molecular pathology of pancreatic neoplasmsManagement of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphologyNeuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancyGenetics of pancreatic neuroendocrine tumors: implications for the clinic.Immunohistochemical analysis of the Wnt/β-catenin signaling pathway in pancreatic neuroendocrine neoplasmsWell-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literatureNeuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate.Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms.Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors.Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index.The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.Treatment of a mixed acinar-endocrine carcinoma with uptake on 68Gallium-DOTATOC positron emission tomography-computed tomography: A case reportMolecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study.Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer.Neuroendocrine neoplasms: a brief overview emphasizing gastroenteropancreatic tumors.Challenges Staging Neuroendocrine Tumors of the Pancreas, Jejunum and Ileum, and Appendix.Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.Prognoses in patients with primary gastrointestinal neuroendocrine neoplasms based on the proposed new classification scheme.Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor.Cyto-histology in NET: what is necessary today and what is the future?Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates.Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.
P2860
Q26748615-2CE81853-C546-49DE-941D-9575A5BCC1DFQ28078501-471D99B2-8C10-4292-89FD-8E09F78D45D5Q30238552-165E674E-662A-4DCD-B4CC-555AF94A39B8Q30249051-F8F531FB-561B-4221-A122-98C2F77A85E9Q33901099-B62A8BD0-C419-4ED4-91F1-F3EE35DD03A4Q35771217-37BB0607-04A7-4302-9B01-706CE6320FDAQ36413831-C017AF1A-80BA-492E-BDF6-BEE91CC3944EQ36960581-42523AEA-42CC-47BD-80AC-046221931D60Q37166703-00872585-A11B-4A4A-9914-D2BA0FB4B8ACQ37182620-1310026B-CB37-4030-AEC4-0F3BE6D256D8Q37624511-30F8B2C6-A6F0-4027-BC03-9B44381D99ECQ37631597-A6ABB6A5-3020-4AEE-80E0-59E65FD775A6Q37646677-C5B1EDEA-6516-479B-9EC3-4B9293E4FDDFQ38600057-A57469FD-2442-40EC-ACF9-2DDB931092ACQ38610333-845ACF32-DB21-4338-9B34-470EDA9091F5Q38650864-8FF0DD58-C03E-4967-950C-8736C8B7A54FQ38769603-22451B5A-D543-4F23-BD3A-9C37F1EC5142Q38777613-9714127C-075D-4EDE-A25E-184DB6186DE8Q38835123-EE096217-5F8E-4354-AB0E-19485564576AQ38853033-B126C80C-C5D4-4E88-869D-5D0EE808E8B7Q38902120-3D3E66E0-7473-4B7E-9561-9DFD3510D0F0Q39934413-752DCC61-8737-44A8-A366-5B43F5F2E863Q40395607-C4F33E97-3965-4E06-AE1F-BD3B353BE460Q40453835-ABD8905B-B895-4F3B-B735-8FB4225DCCD0Q40699250-CCCA3B2B-D222-4336-94DC-B65F91002063Q40874923-6EE11B03-4AB8-41D7-B750-2B9CA32D36A6Q40979017-124211D0-3C60-4C40-B051-01EC1A40D6E6Q41198847-9836CBDE-B10E-4CA0-821D-6C0CF3A876CAQ41683785-645BD267-E57B-4390-BC9F-3137CC29B402Q42349019-3D79A821-5256-4D95-B502-D33CA7827C0AQ46919027-BF9CB899-2487-49BF-B9AE-897B44D84B4FQ47218406-1C901274-CDB0-4BDC-AFDE-894E9A748598Q47283973-10D70433-6CA1-45DF-97B0-607BC20591C6Q47594456-99DA557F-4AB7-4964-A31A-1779AA1B8F1CQ47734687-0D086022-02FE-4859-910B-C9CD3155FE52Q47890492-5DA1364B-C3CB-4A6F-9935-70FE5ED4428AQ47965331-57502155-7C41-4DC2-B49D-2388F04D260BQ48088751-98918B36-6AF5-4D4B-A74C-FA6EDE23BB88Q48120130-A0F49790-6713-4751-8D89-D6CAE9646D0AQ48120139-3EE4CCEC-5E66-4716-9D24-0D81701C1337
P2860
The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The high-grade (WHO G3) pancre ...... orly differentiated neoplasms.
@ast
The high-grade (WHO G3) pancre ...... orly differentiated neoplasms.
@en
The high-grade
@nl
type
label
The high-grade (WHO G3) pancre ...... orly differentiated neoplasms.
@ast
The high-grade (WHO G3) pancre ...... orly differentiated neoplasms.
@en
The high-grade
@nl
prefLabel
The high-grade (WHO G3) pancre ...... orly differentiated neoplasms.
@ast
The high-grade (WHO G3) pancre ...... orly differentiated neoplasms.
@en
The high-grade
@nl
P2093
P2860
P50
P1476
The high-grade (WHO G3) pancre ...... oorly differentiated neoplasms
@en
P2093
Alyssa M Krasinskas
David S Klimstra
Kee-Taek Jang
Laura H Tang
Wendy L Frankel
Zhaohai Yang
P2860
P304
P356
10.1097/PAS.0000000000000408
P407
P577
2015-05-01T00:00:00Z